BHST BioHarvest Sciences (BHST) Q2 FY26 earnings call
BioHarvest Sciences announced its first CDMO manufacturing and supply agreement for a rare fragrance, signaling a strategic shift towards accelerating monetization of developed molecules and converting high-value opportunities into recurring revenue. The company is optimizing its D2C VINIA business through pricing changes, new messaging, and product formats, while managing cash carefully to avoid equity-based funding and achieve consolidated EBITDA breakeven in 2027. This pivot emphasizes leveraging existing assets and focusing on high-margin CDMO projects.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.